Please use this identifier to cite or link to this item:
http://dspace.bits-pilani.ac.in:8080/jspui/xmlui/handle/123456789/13479
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gaikwad, Anil Bhanudas | - |
dc.date.accessioned | 2023-12-21T06:35:02Z | - |
dc.date.available | 2023-12-21T06:35:02Z | - |
dc.date.issued | 2020-07 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/abs/pii/S1359644620301689 | - |
dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13479 | - |
dc.description.abstract | Fibrosis is a wound-healing process that results in tissue scarring and organ dysfunction. Several novel mechanisms of fibrogenesis have been discovered recently. In this review, we focus on the role of poly-ADP ribose polymerase (PARP) in major organ fibrosis, such as lungs, heart, liver, and kidneys. PARP is a dynamic enzyme that modulates different cellular proteins by the addition of PAR groups and mediates an array of cellular events in both normal physiological and pathophysiological states. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) recently approved several PARP inhibitors, such as olaparib, niraparib, talazoparib, and rucaparib, for the treatment of ovarian and germline BRCA-mutant breast cancers. Consequently, repurposing these drugs could provide an opportunity to counter organ fibrosis. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.subject | Pharmacy | en_US |
dc.subject | European Medicines Agency (EMA) | en_US |
dc.subject | Poly-ADP ribose polymerase (PARP) | en_US |
dc.title | ‘PARP’ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors | en_US |
dc.type | Article | en_US |
Appears in Collections: | Department of Pharmacy |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.